GlassScriptPhysician profile
Julius Albert Kato
NPI 1124098819
$4,577.73
in general payments reported to CMS, 2019-2025
30 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $391 · 2021: $733 · 2022: $589 · 2023: $657 · 2024: $739 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $690.43 | 2021-2025 | Onyx Frontier, Symplicity G3, Ffrangio |
| Boston Scientific Corporation | $608.68 | 2019-2025 | Jetstream Sc, Accolade Sr, Latitude Communicator Power Supply |
| Abbott Laboratories | $445.06 | 2019-2024 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $407.53 | 2020-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $359.70 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $310.98 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $284.50 | 2019-2025 | |
| Medtronic Vascular, INC. | $243.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $154.95 | 2019-2023 | Xarelto |
| Philips North America LLC | $150.53 | 2019-2025 | Azurion 7 M20 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.81 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $113.79 | 2022-2025 | Camzyos, Eliquis |
| Regeneron Healthcare Solutions, INC. | $109.03 | 2019 | |
| Amgen INC. | $92.83 | 2019-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $65.54 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.63 | 2025 | |
| Gilead Sciences, INC. | $40.39 | 2019 | |
| Novo Nordisk INC | $37.84 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $35.74 | 2025 | |
| W. L. Gore & Associates, INC. | $33.74 | 2021-2025 | Gore Cardioform Septal Occluder |
| Heartflow, INC. | $32.58 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $32.29 | 2022-2023 | Rotarexs 6 F X 135 Cm |
| Terumo Medical Corporation | $30.55 | 2021-2023 | Glidewire |
| Alnylam Pharmaceuticals INC. | $26.96 | 2025 | Amvuttra |
| Penumbra, INC. | $23.91 | 2025 | Indigo System |
| Merck Sharp & Dohme LLC | $17.03 | 2023 | Verquvo |
| Akcea Therapeutics, INC. | $16.85 | 2021 | |
| Chiesi USA, INC. | $15.10 | 2025 | Cleviprex, Kengreal |
| Sanofi-Aventis U.S. LLC | $14.97 | 2019 | |
| Endologix LLC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Kato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.